A pragmatic and commercially driven leader with over 20 years of experience in the pharmaceutical, veterinary and capital markets sectors.

She is experienced in operational and marketing roles at Pfizer, Novartis and Zoetis.

A successful track record of product development, registration & product marketing launches, including commercialisation of numerous market leading blockbuster medicines.

Specialising in M&A, building high performance teams and cultures, corporate development and legal. Having worked with a wide range of ASX listed companies in the last 7 years executing capital raising and investor relations strategies. She also completed the Pfizer Inc, 1-year internal leadership program in 2012.

30 years in the global pharmaceuticals industry.

Previously Vice President of Global Business Development and Licensing at Novartis, and Non-Executive Director of SymBio Pharmaceuticals Limited.

Advisor to VOX Telehealth, BioHealthonomics Inc and Transparency Life Sciences.

Mr Buttula is a prominent investor and has over 30 years executive and director experience across many sectors of business including biotechnology. He brings considerable skills to Myopharm as it moves forward on executing its business plans.

Mr Buttula’s former roles include Managing Director of Lonsdale Securities and Investors Mutual, companies which he founded. He has served on numerous public listed company boards including Investorfirst, now HUB24 (ASX:HUB), and Non-Executive Director at Imugene (ASX IMU). Mr Buttula currently serves as Chairman at Rhythm Biosciences Limited (ASX: RHY), HITIQ Limited (ASX:HIQ) and OncoSil Medical Ltd (ASX:OSL).

Myopharm outsources its finance and company secretarial requirements to a specialist public practice, 'The CFO Solution'. Mr Phillip Hains brings over 30 years of experience in corporate secretarial, accounting and general management through his firm The CFO Solution, a boutique professional services firm for listed companies. Mr Hains is currently the Company Secretary of several ASX listed companies.